Edithistory:Andrea Giunti
From EverybodyWiki Bios & Wiki
| oldid | date/time | username | edit summary |
|---|---|---|---|
| 1370720032 | 2026-08-22T18:40:53Z | Sulfurboy | Declining submission: bio - Submission is about a person not yet shown to meet notability guidelines |
| 1370642920 | 2026-08-22T06:50:43Z | Sulfurboy | Marking submission as under review |
| 1370642891 | 2026-08-22T06:50:22Z | Sulfurboy | Filled in 0 bare reference(s) with reFill 2 |
| 1370642797 | 2026-08-22T06:48:59Z | ~2026-45780-50 | |
| 1358602816 | 2026-06-09T19:35:18Z | JJMC89 bot | Add {{drafts moved from mainspace}} |
| 1358602787 | 2026-06-09T19:35:00Z | Seloumadin | |
| 1358602542 | 2026-06-09T19:33:03Z | Seloumadin | |
| 1358602372 | 2026-06-09T19:31:44Z | Seloumadin | Seloumadin moved page [[Andrea Giunti]] to [[Draft:Andrea Giunti]]: Working on |
| 1358550938 | 2026-06-09T12:00:29Z | Tom.Reding | /* References */ +{{DEFAULTSORT:Giunti, Andrea}}; [[WP:GenFixes]] & cleanup on |
| 1358548389 | 2026-06-09T11:32:48Z | Tom.Reding | [[WP:GenFixes]]/cleanup |
| 1358541692 | 2026-06-09T10:15:11Z | Mariamnei | Added tags to the page using [[Wikipedia:Page Curation|Page Curation]] (more footnotes) |
| 1358467648 | 2026-06-08T21:45:25Z | Seloumadin | |
| 1358467492 | 2026-06-08T21:44:11Z | Seloumadin | Adding [[Wikipedia:Short description|short description]]: "Italian publisher" |
| 1358467404 | 2026-06-08T21:43:17Z | Seloumadin | |
| 1358467076 | 2026-06-08T21:40:08Z | Seloumadin | source fix |
| 1358467011 | 2026-06-08T21:39:28Z | Seloumadin | Seloumadin moved page [[User:Seloumadin/sandbox]] to [[Andrea Giunti]]: Move to mainspace |
| 1358466960 | 2026-06-08T21:39:08Z | Seloumadin | |
| 1358466943 | 2026-06-08T21:38:57Z | Seloumadin | categories |
| 1358466724 | 2026-06-08T21:37:17Z | Seloumadin | moved source |
| 1358466520 | 2026-06-08T21:35:37Z | Seloumadin | awards section |
| 1358466124 | 2026-06-08T21:31:45Z | Seloumadin | add more to career |
| 1358464698 | 2026-06-08T21:22:45Z | Seloumadin | Career section |
| 1358464013 | 2026-06-08T21:17:49Z | Seloumadin | Education section |
| 1358463564 | 2026-06-08T21:14:09Z | Seloumadin | Create the lead for a new article |
| 1358463106 | 2026-06-08T21:10:10Z | Seloumadin | [[WP:AES|←]]Blanked the page |
| 1355641130 | 2026-05-23T01:22:09Z | Bearcat | [[WP:USERNOCAT]] |
| 1355621591 | 2026-05-22T22:54:54Z | Seloumadin | categories |
| 1355621459 | 2026-05-22T22:54:07Z | Seloumadin | categories |
| 1355620321 | 2026-05-22T22:45:13Z | Seloumadin | |
| 1355619873 | 2026-05-22T22:41:23Z | Seloumadin | Image of Prucalopride skeletal structure |
| 1355619757 | 2026-05-22T22:40:21Z | Seloumadin | Image of Serotonin skeletal structure |
| 1355619098 | 2026-05-22T22:34:53Z | Seloumadin | |
| 1355619033 | 2026-05-22T22:34:24Z | Seloumadin | |
| 1355618941 | 2026-05-22T22:33:37Z | Seloumadin | Add the External links section |
| 1355618870 | 2026-05-22T22:33:03Z | Seloumadin | See also section |
| 1355618772 | 2026-05-22T22:32:16Z | Seloumadin | See also section |
| 1355617674 | 2026-05-22T22:23:51Z | Seloumadin | Source |
| 1355617483 | 2026-05-22T22:22:28Z | Seloumadin | Source |
| 1355617160 | 2026-05-22T22:19:55Z | Seloumadin | Source |
| 1355617016 | 2026-05-22T22:18:47Z | Seloumadin | Add the infobox |
| 1355615617 | 2026-05-22T22:07:24Z | Seloumadin | |
| 1355615397 | 2026-05-22T22:05:40Z | Seloumadin | |
| 1355615188 | 2026-05-22T22:03:37Z | Seloumadin | |
| 1355614828 | 2026-05-22T22:00:58Z | Seloumadin | |
| 1355613972 | 2026-05-22T21:54:51Z | Seloumadin | |
| 1355613890 | 2026-05-22T21:54:16Z | Seloumadin | Added dedicated QT/QTc cardiac safety study finding confirming no QT prolongation. |
| 1355613757 | 2026-05-22T21:53:28Z | Seloumadin | QT/QTc cardiac safety study |
| 1355613535 | 2026-05-22T21:52:00Z | Seloumadin | |
| 1355613398 | 2026-05-22T21:51:17Z | Seloumadin | QT/QTc study section |
| 1355613186 | 2026-05-22T21:49:57Z | Seloumadin | |
| 1355613015 | 2026-05-22T21:48:55Z | Seloumadin | |
| 1355612857 | 2026-05-22T21:47:56Z | Seloumadin | |
| 1355612733 | 2026-05-22T21:47:09Z | Seloumadin | Safety findings. |
| 1355612487 | 2026-05-22T21:45:40Z | Seloumadin | SBM improvement |
| 1355612227 | 2026-05-22T21:43:57Z | Seloumadin | The FDA composite responder rate |
| 1355611904 | 2026-05-22T21:41:52Z | Seloumadin | |
| 1355611750 | 2026-05-22T21:41:09Z | Seloumadin | Rome IV, 12-week study |
| 1355611578 | 2026-05-22T21:40:22Z | Seloumadin | Rome IV, 12-week study |
| 1355611398 | 2026-05-22T21:39:22Z | Seloumadin | Rome IV, 12-week study |
| 1355611099 | 2026-05-22T21:37:30Z | Seloumadin | Add "Phase 2b study (2017)" heading |
| 1355610976 | 2026-05-22T21:36:29Z | Seloumadin | |
| 1355610828 | 2026-05-22T21:35:29Z | Seloumadin | |
| 1355610710 | 2026-05-22T21:34:42Z | Seloumadin | |
| 1355610574 | 2026-05-22T21:33:52Z | Seloumadin | The abdominal symptoms |
| 1355610477 | 2026-05-22T21:33:08Z | Seloumadin | Baseline in weekly CSBM frequency |
| 1355610270 | 2026-05-22T21:31:48Z | Seloumadin | Clinical trial results including dosing, CSBM outcomes, |
| 1355609864 | 2026-05-22T21:29:13Z | Seloumadin | |
| 1355609776 | 2026-05-22T21:28:39Z | Seloumadin | Rome III, 4-week study |
| 1355609420 | 2026-05-22T21:26:17Z | Seloumadin | Phase 2a study (2012–2013) Heading |
| 1355609018 | 2026-05-22T21:23:50Z | Seloumadin | Add "Clinical trials" section |
| 1355608760 | 2026-05-22T21:22:08Z | Seloumadin | |
| 1355608687 | 2026-05-22T21:21:42Z | Seloumadin | |
| 1355608522 | 2026-05-22T21:20:41Z | Seloumadin | Source |
| 1355608340 | 2026-05-22T21:19:42Z | Seloumadin | |
| 1355608190 | 2026-05-22T21:18:45Z | Seloumadin | The Metabolite profiles |
| 1355608075 | 2026-05-22T21:18:10Z | Seloumadin | |
| 1355607988 | 2026-05-22T21:17:35Z | Seloumadin | |
| 1355607927 | 2026-05-22T21:17:00Z | Seloumadin | |
| 1355607890 | 2026-05-22T21:16:41Z | Seloumadin | plasma concentration |
| 1355607271 | 2026-05-22T21:12:01Z | Seloumadin | |
| 1355607119 | 2026-05-22T21:10:51Z | Seloumadin | the subjects |
| 1355606660 | 2026-05-22T21:07:43Z | Seloumadin | |
| 1355606557 | 2026-05-22T21:07:00Z | Seloumadin | pharmacokinetic section with absorption, |
| 1355605449 | 2026-05-22T20:59:45Z | Seloumadin | A new section "Pharmacokinetics" |
| 1355601446 | 2026-05-22T20:31:42Z | Seloumadin | |
| 1355601387 | 2026-05-22T20:31:18Z | Seloumadin | |
| 1355601285 | 2026-05-22T20:30:44Z | Seloumadin | Source the Gastrointestinal effects section |
| 1355601131 | 2026-05-22T20:29:57Z | Seloumadin | |
| 1355600695 | 2026-05-22T20:27:15Z | Seloumadin | The doses improved clonidine- and morphine-induced in mice |
| 1355600255 | 2026-05-22T20:24:30Z | Seloumadin | Gastrointestinal effects based on doses In mice |
| 1355600043 | 2026-05-22T20:23:17Z | Seloumadin | Gastrointestinal effects based on doses |
| 1355599837 | 2026-05-22T20:21:41Z | Seloumadin | Gastrointestinal effects |
| 1355599380 | 2026-05-22T20:18:10Z | Seloumadin | Add "Gastrointestinal effects" heading |
| 1355599015 | 2026-05-22T20:15:39Z | Seloumadin | |
| 1355598923 | 2026-05-22T20:15:03Z | Seloumadin | Source |
| 1355598772 | 2026-05-22T20:14:01Z | Seloumadin | Concern in the development of 5-HT4 receptor agonists for cardiovascular safety 4 |
| 1355598635 | 2026-05-22T20:13:03Z | Seloumadin | Concern in the development of 5-HT4 receptor agonists for cardiovascular safety 3 |
| 1355598458 | 2026-05-22T20:11:52Z | Seloumadin | Concern in the development of 5-HT4 receptor agonists for cardiovascular safety |
| 1355598154 | 2026-05-22T20:10:13Z | Seloumadin | |
| 1355597989 | 2026-05-22T20:09:25Z | Seloumadin | Concern in the development of 5-HT4 receptor agonists for cardiovascular safety |
| 1355597045 | 2026-05-22T20:04:34Z | Seloumadin | Add the "Cardiovascular safety" heading |
| 1355596883 | 2026-05-22T20:03:49Z | Seloumadin | Describe the affinity for 5-HT4 receptors |
| 1355596324 | 2026-05-22T20:00:59Z | Seloumadin | reused the source for this part |
| 1355596174 | 2026-05-22T20:00:20Z | Seloumadin | |
| 1355596124 | 2026-05-22T20:00:07Z | Seloumadin | |
| 1355595806 | 2026-05-22T19:58:31Z | Seloumadin | Add source |
| 1355595577 | 2026-05-22T19:57:12Z | Seloumadin | |
| 1355594385 | 2026-05-22T19:51:27Z | Seloumadin | Add the heading "Mechanism of action" |
| 1355594257 | 2026-05-22T19:50:47Z | Seloumadin | The first section for the new article "Pharmacology" |
| 1355594029 | 2026-05-22T19:49:45Z | Seloumadin | |
| 1355593953 | 2026-05-22T19:49:18Z | Seloumadin | |
| 1355593848 | 2026-05-22T19:48:38Z | Seloumadin | The lead also |
| 1355593154 | 2026-05-22T19:44:23Z | Seloumadin | The developer sourced |
| 1355592611 | 2026-05-22T19:41:09Z | Seloumadin | References section for the new article |
| 1355592452 | 2026-05-22T19:40:26Z | Seloumadin | Added source for the lead |
| 1355592341 | 2026-05-22T19:39:54Z | Seloumadin | |
| 1355591842 | 2026-05-22T19:36:46Z | Seloumadin | Create the lead for a new article |
| 1353825234 | 2026-05-12T16:10:31Z | Seloumadin | [[WP:AES|←]]Blanked the page |
| 1353824787 | 2026-05-12T16:06:27Z | Seloumadin | test |
| 1353824256 | 2026-05-12T16:01:36Z | Seloumadin | [[WP:AES|←]]Replaced content with '{{User sandbox}} <!-- EDIT BELOW THIS LINE -->' |
| 1353824204 | 2026-05-12T16:01:06Z | Seloumadin | test |
| 1353146613 | 2026-05-08T13:30:01Z | Seloumadin | |
| 1353146458 | 2026-05-08T13:28:47Z | Seloumadin | |
| 1353146371 | 2026-05-08T13:28:01Z | Seloumadin | [[WP:AES|←]]Created page with '{{User sandbox}} <!-- EDIT BELOW THIS LINE -->{| class="wikitable plainrowheaders" |- ! scope="col" | Section number ! scope="col" | km ! scope="col" | mi ! scope="col" | Section name |- ! scope="row" style="text-align: right;" | 12801 | 13.948 | 8.667 | [[Golubinci]] – [[Pećinci]] ([[Subotište]]) {{jctbtm|col=4}}' |
